BA 1301
Alternative Names: BA-1301; Claudin 18.2 ADC - Shandong Boan Biotechnology; PR-301Latest Information Update: 31 Mar 2026
At a glance
- Originator Shandong Boan Biotechnology
- Class Antibodies; Antineoplastics; Auristatins; Drug conjugates; Immunoconjugates; Immunotoxins
- Mechanism of Action Apoptosis stimulants; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Yes - Gastric cancer; Pancreatic cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 17 Oct 2025 Efficacy, pharmacokinetic and adverse events data from a phase I trial in Solid tumours presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)
- 03 Oct 2025 BA-1301 is still in phase-I trials for Solid tumours in China (NCT06927349)
- 28 Aug 2025 BA 1301 receives Orphan Drug status for Gastric cancer in USA , prior to August 2025